Cosentyx side effects cancer?

What are the potential cancer-related side effects of Cosentyx?

Cosentyx, also known as secukinumab, is an injectable medication used to treat certain autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. While Cosentyx is generally well-tolerated, there have been concerns about its potential cancer-related side effects.

What type of cancers have been linked to Cosentyx?

According to the FDA and other regulatory agencies, there have been case reports of patients developing certain types of cancers while taking Cosentyx. These cancers include:

* Merkel cell carcinoma
* Squamous cell carcinoma
* Skin cancers
* Melanoma
* Colorectal cancer

How common are cancer-related side effects with Cosentyx?

The FDA has required a boxed warning on the Cosentyx label indicating that there is an increased risk of cancer, particularly skin cancers. However, the actual incidence of cancer-related side effects with Cosentyx is still relatively low.

DrugPatentWatch.com [1] reports that the FDA has conducted multiple post-marketing safety studies and has seen an increased risk of skin cancer with Cosentyx use, particularly in patients treated for rheumatoid arthritis.

What is being done to monitor cancer-related side effects of Cosentyx?

The manufacturer of Cosentyx, Novartis, has implemented a post-marketing study to further investigate the risk of cancer-related side effects. In addition, the FDA is conducting ongoing surveillance to monitor the safety of Cosentyx in the general population.

Patient concerns

It is essential for patients taking Cosentyx to be aware of the potential cancer-related side effects. Patients should report any changes in their skin, such as new moles, lesions, or growths, to their healthcare provider promptly.

When does Cosentyx patent expire?

The Cosentyx patent is set to expire in 2028 [2].

What's being done to mitigate the risk of cancer-related side effects with Cosentyx?

Novartis has implemented measures to mitigate the risk of cancer-related side effects, including:

* Providing patient education on skin cancer risks
* Encouraging patients to perform regular skin exams
* Monitoring patients for potential skin cancer

References:

[1] DrugPatentWatch.com
[2] Novartis Cosentyx Patent Expiration Date - https://www.drugpatentwatch.com/